Bayer BAYRY announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.

While FDA drug and device reviewers and inspectors were protected from layoffs, drug reviews are likely to be affected, ...

J.P. Morgan analyst Richard Vosser reiterated a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

The U.S. Food And Drug Administration (FDA) granted full approval to Bayer AG’s (OTC:BAYRY) Vitrakvi (larotrectinib) for ...

UBS analyst Matthew Weston maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF104.00. The ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.